Could Biotelemetry Inc (NASDAQ:BEAT) Go Down After Its Newest Short Interest Report?

May 17, 2018 - By Tina Thibodeau

BioTelemetry, Inc. (NASDAQ:BEAT) Logo

Investors sentiment decreased to 0.88 in Q4 2017. Its down 0.40, from 1.28 in 2017Q3. It dropped, as 47 investors sold BioTelemetry, Inc. shares while 57 reduced holdings. 27 funds opened positions while 65 raised stakes. 27.71 million shares or 8.71% more from 25.49 million shares in 2017Q3 were reported.
Perkins Cap Inc invested in 15,000 shares. Pnc Financial Service Gp stated it has 0% in BioTelemetry, Inc. (NASDAQ:BEAT). Sei Invests reported 9,964 shares. Envestnet Asset Management holds 0% or 19,862 shares in its portfolio. Vident Investment Advisory Ltd Liability Corp holds 20,471 shares or 0.03% of its portfolio. Voya Investment Mgmt Llc has invested 0% of its portfolio in BioTelemetry, Inc. (NASDAQ:BEAT). Price T Rowe Associates Md has 0% invested in BioTelemetry, Inc. (NASDAQ:BEAT). Strs Ohio stated it has 138,000 shares. Thompson Siegel And Walmsley Ltd Com has invested 0.19% in BioTelemetry, Inc. (NASDAQ:BEAT). Intrust Bancorp Na holds 7,978 shares. Comerica Bankshares has invested 0.01% of its portfolio in BioTelemetry, Inc. (NASDAQ:BEAT). The Montana-based First Interstate Commercial Bank has invested 0% in BioTelemetry, Inc. (NASDAQ:BEAT). Gabelli Funds Ltd Llc holds 0.02% or 98,000 shares. Virginia Retirement Sys Et Al has 54,300 shares for 0.02% of their portfolio. Moreover, Art Lc has 0.01% invested in BioTelemetry, Inc. (NASDAQ:BEAT).

The stock of Biotelemetry Inc (NASDAQ:BEAT) registered a decrease of 5.43% in short interest. BEAT’s total short interest was 3.26M shares in May as published by FINRA. Its down 5.43% from 3.45M shares, reported previously. With 419,000 shares average volume, it will take short sellers 8 days to cover their BEAT’s short positions. The short interest to Biotelemetry Inc’s float is 10.31%.

The stock increased 0.86% or $0.35 during the last trading session, reaching $41.15. About 165,592 shares traded. BioTelemetry, Inc. (NASDAQ:BEAT) has risen 11.39% since May 17, 2017 and is uptrending. It has underperformed by 0.16% the S&P500.

BioTelemetry, Inc. provides cardiac monitoring, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The company has market cap of $1.35 billion. The firm operates in three divisions: Healthcare, Research, and Technology. It currently has negative earnings. The Healthcare segment focuses on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders.

BioTelemetry, Inc. (NASDAQ:BEAT) Ratings Coverage

Among 2 analysts covering BioTelemetry (NASDAQ:BEAT), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. BioTelemetry had 2 analyst reports since November 30, 2017 according to SRatingsIntel. The rating was maintained by Raymond James on Thursday, November 30 with “Buy”. Dougherty maintained it with “Buy” rating and $41.0 target in Friday, February 23 report.

More recent BioTelemetry, Inc. (NASDAQ:BEAT) news were published by: Globenewswire.com which released: “BioTelemetry, Inc. Reports First Quarter 2018 Financial Results” on April 25, 2018. Also Seekingalpha.com published the news titled: “BioTelemetry’s (BEAT) CEO Joseph Capper on Q1 2018 Results – Earnings Call Transcript” on April 26, 2018. Benzinga.com‘s news article titled: “Benzinga’s Daily Biotech Pulse: FDA Panel Nod For Akcea, Synergy’s Revenue Miss, FDA Warns E-Liquid Makers Again” with publication date: May 11, 2018 was also an interesting one.

BioTelemetry, Inc. (NASDAQ:BEAT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: